Literature DB >> 10980234

Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

J T Parissis1, S Adamopoulos, K F Venetsanou, D G Mentzikof, S M Karas, D T Kremastinos.   

Abstract

In this report, we showed for the first time that granulocyte-macrophage colony-stimulating factor plasma levels are elevated in patients with severe heart failure, and these levels are correlated well with neurohormonal activation and hemodynamic deterioration characterizing this syndrome.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10980234     DOI： 10.1016/s0002-9149(00)01062-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  4 in total

1.  Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor.

Authors:  Hiroaki Ohnaka; Hitoshi Tsukamoto; Toshiaki Nakamura; Ryoichi Yano; Kyohei Watanabe; Toshiaki Igarashi; Nobuyuki Goto; Mikio Masada
Journal:  Int J Clin Pharm       Date:  2012-09-26

Review 2.  Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond.

Authors:  Santosh K Sanganalmath; Ahmed Abdel-Latif; Roberto Bolli; Yu-Ting Xuan; Buddhadeb Dawn
Journal:  Basic Res Cardiol       Date:  2011-05-04       Impact factor: 17.165

3.  The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes.

Authors:  Atsushi Anzai; Jennifer L Choi; Shun He; Ashley M Fenn; Manfred Nairz; Sara Rattik; Cameron S McAlpine; John E Mindur; Christopher T Chan; Yoshiko Iwamoto; Benoit Tricot; Gregory R Wojtkiewicz; Ralph Weissleder; Peter Libby; Matthias Nahrendorf; James R Stone; Burkhard Becher; Filip K Swirski
Journal:  J Exp Med       Date:  2017-10-04       Impact factor: 14.307

4.  Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.

Authors:  Jianjiao Ni; Yue Zhou; Lin Wu; Xinghao Ai; Xiaorong Dong; Qian Chu; Chengbo Han; Xiaofei Wang; Zhengfei Zhu
Journal:  Radiat Oncol       Date:  2021-09-15       Impact factor: 3.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.